Last reviewed · How we verify
TPX-105
TPX-105 is a selective inhibitor of transient receptor potential (TRP) channels involved in pain signaling.
TPX-105 is a selective inhibitor of transient receptor potential (TRP) channels involved in pain signaling. Used for Neuropathic pain (Phase 3), Chronic pain conditions.
At a glance
| Generic name | TPX-105 |
|---|---|
| Also known as | Autologous human dermal fibroblasts |
| Sponsor | Tego Science, Inc. |
| Drug class | TRP channel inhibitor |
| Target | TRP channels (specific subtype proprietary to Tego Science) |
| Modality | Biologic |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
TPX-105 targets specific TRP channel subtypes that mediate nociceptive (pain) signaling in peripheral sensory neurons. By blocking these ion channels, the drug reduces the transmission of pain signals to the central nervous system, providing analgesic effects without the systemic side effects associated with opioids or traditional NSAIDs.
Approved indications
- Neuropathic pain (Phase 3)
- Chronic pain conditions
Common side effects
- Local application site reactions
- Transient sensory changes
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |